McKesson Corporation reported a strong financial performance for the fiscal year ending March 31, 2026, with total revenues reaching $403.4 billion, a 12% increase from $359.1 billion in the previous year. The company's gross profit also rose by 9% to $14.6 billion, while net income attributable to McKesson Corporation surged 45% to $4.8 billion, translating to diluted earnings per share of $38.38, up from $25.72 in fiscal 2025. The increase in revenues was primarily driven by growth in the North American Pharmaceutical segment, which saw an 11% rise in sales, and a significant 31% increase in the Oncology & Multispecialty segment, attributed to higher specialty pharmaceutical sales and the addition of new providers.
In terms of operational changes, McKesson implemented a new segment reporting structure in the second quarter of fiscal 2026, which now includes four reportable segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company also completed several strategic acquisitions, including a controlling interest in PRISM Vision for $875 million and Core Ventures for $2.5 billion, both of which are expected to enhance its oncology and specialty care offerings. Additionally, McKesson announced plans to separate its Medical-Surgical Solutions segment into an independent company, with a minority stake being acquired by Apollo Global Management for approximately $1.25 billion.
The company’s operational metrics reflected positive trends, with a notable increase in customer engagement. McKesson's Prescription Technology Solutions segment reported helping patients access their medications over 135 million times, saving approximately $10 billion on brand and specialty medications. The company also maintained a workforce of over 43,000 employees globally, with a focus on enhancing employee engagement and retention through various training and development programs.
Looking ahead, McKesson expressed optimism about its future performance, citing ongoing investments in technology and operational efficiencies. The company anticipates continued revenue growth driven by market expansion and the successful integration of its recent acquisitions. However, it also acknowledged potential risks related to regulatory changes, market conditions, and ongoing litigation, particularly concerning opioid-related claims, which could impact its financial position. The company remains committed to navigating these challenges while focusing on its core healthcare services to improve patient outcomes.
About MCKESSON CORP
McKesson Corporation is a global healthcare services and distribution company providing pharmaceuticals, medical-surgical supplies, and technology solutions. Its core segments include U.S. Pharmaceutical distribution, Prescription Technology Solutions, Medical-Surgical Solutions, and international operations in Canada and Norway. The company supports healthcare providers, pharmacies, biopharma partners, and government agencies with logistics, supply chain management, clinical support, and innovative technology to improve health outcomes and operational efficiency.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.